[go: up one dir, main page]

BR0208924A - Uso de conjugados de ácido graxo de sal biliar ou de ácido biliar - Google Patents

Uso de conjugados de ácido graxo de sal biliar ou de ácido biliar

Info

Publication number
BR0208924A
BR0208924A BR0208924-6A BR0208924A BR0208924A BR 0208924 A BR0208924 A BR 0208924A BR 0208924 A BR0208924 A BR 0208924A BR 0208924 A BR0208924 A BR 0208924A
Authority
BR
Brazil
Prior art keywords
bile
acid
salt
fatty acid
conjugates
Prior art date
Application number
BR0208924-6A
Other languages
English (en)
Inventor
Tuvia Gilat
Original Assignee
Galmed Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galmed Int Ltd filed Critical Galmed Int Ltd
Publication of BR0208924A publication Critical patent/BR0208924A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"USO DE CONJUGADOS DE áCIDO GRAXO DE SAL BILIAR OU DE áCIDO BILIAR". A presente invenção refere-se ao uso de um conjugado de ácido graxo biliar ou de ácido biliar da fórmula geral II W-X-G, em que G é um radical de sal biliar ou de ácido biliar, que, se desejado, é conjugado na posição 24 com um aminoácido adequado, W significa um ou dois radicais de ácido graxo tendo de 14-22 átomos de carbono e X significa um membro de ligação adequado ou para uma ligação de C=C direta entre o dito radical de sal biliar ou de ácido biliar e o(s) ácido(s) graxo(s) ou de uma composição farmacêutica compreendendo o mesmo para a redução de colesterol no sangue, para o tratamento de fígado graxo, hiperglicemia e diabetes.
BR0208924-6A 2001-04-17 2002-04-15 Uso de conjugados de ácido graxo de sal biliar ou de ácido biliar BR0208924A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL142650A IL142650A (en) 1998-04-08 2001-04-17 Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
PCT/IL2002/000303 WO2002083147A1 (en) 2001-04-17 2002-04-15 Use of bile acid or bile salt fatty acid conjugates

Publications (1)

Publication Number Publication Date
BR0208924A true BR0208924A (pt) 2004-04-20

Family

ID=11075322

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208924-6A BR0208924A (pt) 2001-04-17 2002-04-15 Uso de conjugados de ácido graxo de sal biliar ou de ácido biliar

Country Status (24)

Country Link
US (2) US7501403B2 (pt)
EP (2) EP1379254B1 (pt)
JP (1) JP4324706B2 (pt)
KR (1) KR100883080B1 (pt)
CN (1) CN1259918C (pt)
AT (2) ATE432705T1 (pt)
AU (2) AU2002307771B2 (pt)
BR (1) BR0208924A (pt)
CA (2) CA2703688C (pt)
CY (1) CY1106853T1 (pt)
CZ (2) CZ300489B6 (pt)
DE (2) DE60220775T2 (pt)
DK (2) DK1379254T3 (pt)
EA (1) EA007565B1 (pt)
ES (2) ES2328966T3 (pt)
HU (1) HU230548B1 (pt)
IL (1) IL142650A (pt)
MX (1) MXPA03009553A (pt)
NO (2) NO333910B1 (pt)
NZ (1) NZ528868A (pt)
PL (2) PL205057B1 (pt)
PT (2) PT1379254E (pt)
UA (1) UA78699C2 (pt)
WO (1) WO2002083147A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142650A (en) 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
US8975246B2 (en) 2001-04-17 2015-03-10 Galmed Research And Development Ltd. Bile acid or bile salt fatty acid conjugates
WO2009013334A1 (en) * 2007-07-25 2009-01-29 Medizinische Universität Graz Use of nor-bile acids in the treatment of arteriosclerosis
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
MX2011007393A (es) 2009-01-12 2011-10-06 Biokier Inc Composicion y metodo para el tratamiento de la diabetes.
WO2010086864A1 (en) 2009-02-02 2010-08-05 Galmed International Ltd. Methods and compositions for treating alzheimer's disease
US20120202890A1 (en) 2011-02-08 2012-08-09 Nian Wu Polymer-carbohydrate-lipid conjugates
MX2014013150A (es) 2012-05-01 2015-05-11 Catabasis Pharmaceuticals Inc Conjugados de acidos grasos de estatina y agonistas fxr, composiciones y metodos de uso.
CN103571617A (zh) * 2012-07-26 2014-02-12 丰益(上海)生物技术研发中心有限公司 改进的动物油脂加工工艺
KR101702251B1 (ko) * 2012-11-29 2017-02-02 에스티팜 주식회사 신규한 소포 수송에 이용하기 위한 담즙산 올리고머 결합체 및 이의 용도
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
WO2016199137A1 (en) * 2015-06-10 2016-12-15 Galmed Research And Development Ltd. Low dose compositions of aramchol salts
CN110437298A (zh) * 2013-12-04 2019-11-12 盖尔梅德研究与发展有限公司 Aramchol盐
EP3148549A4 (en) * 2014-06-01 2017-11-15 Galmed Research and Development Ltd. Fatty acid bile acid conjugates for treatment of lipodystrophy
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CN116687850A (zh) 2022-02-24 2023-09-05 甘莱制药有限公司 包含环状膦酸酯化合物的药物组合物及其制备方法与用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859437A (en) * 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels
US3856953A (en) * 1973-05-15 1974-12-24 Intellectual Property Dev Corp Method of treating fatty liver
IT1167478B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido ursodesossicolico
IT1167479B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido chenodesossicolico
JPS6164701A (ja) * 1984-09-06 1986-04-03 Meito Sangyo Kk カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5278320A (en) * 1992-09-11 1994-01-11 Merck & Co., Inc. Cholesterol lowering compounds produced by directed biosynthesis
DE4432708A1 (de) * 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
WO1999022728A1 (en) * 1997-10-31 1999-05-14 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
IL142650A (en) 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
IL123998A (en) 1998-04-08 2004-09-27 Galmed Int Ltd Conjugates of bile salts and pharmaceutical preparations containing them
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドｘ受容体活性化剤

Also Published As

Publication number Publication date
CA2703688C (en) 2012-07-31
CZ20032710A3 (cs) 2004-04-14
CY1106853T1 (el) 2012-05-23
IL142650A0 (en) 2002-03-10
UA78699C2 (en) 2007-04-25
NO20131219L (no) 2003-11-28
PL366585A1 (en) 2005-02-07
NO20034609L (no) 2003-11-28
DE60232559D1 (de) 2009-07-16
JP4324706B2 (ja) 2009-09-02
DE60220775D1 (de) 2007-08-02
NO20034609D0 (no) 2003-10-15
EA007565B1 (ru) 2006-12-29
CA2444266A1 (en) 2002-10-24
MXPA03009553A (es) 2004-05-24
DK1790346T3 (da) 2009-10-12
IL142650A (en) 2007-06-03
AU2007200191A1 (en) 2007-02-08
DE60220775T2 (de) 2008-03-06
AU2002307771B2 (en) 2006-10-19
EP1790346B1 (en) 2009-06-03
PT1790346E (pt) 2009-09-04
HUP0400801A3 (en) 2012-09-28
US8110564B2 (en) 2012-02-07
EA200301017A1 (ru) 2005-04-28
EP1790346A2 (en) 2007-05-30
US20040121993A1 (en) 2004-06-24
ATE365044T1 (de) 2007-07-15
NZ528868A (en) 2005-09-30
US7501403B2 (en) 2009-03-10
ES2328966T3 (es) 2009-11-19
NO335087B1 (no) 2014-09-08
CZ2008296A3 (pt) 2004-04-14
PL205057B1 (pl) 2010-03-31
CA2444266C (en) 2010-07-27
ATE432705T1 (de) 2009-06-15
WO2002083147A1 (en) 2002-10-24
DK1379254T3 (da) 2007-10-15
HU230548B1 (hu) 2016-11-28
AU2007200191B2 (en) 2008-09-04
CN1259918C (zh) 2006-06-21
KR100883080B1 (ko) 2009-02-10
EP1790346A3 (en) 2007-08-22
EP1379254A1 (en) 2004-01-14
CA2703688A1 (en) 2002-10-24
US20090149537A1 (en) 2009-06-11
PT1379254E (pt) 2007-07-10
HUP0400801A2 (hu) 2004-08-30
CZ300489B6 (cs) 2009-06-03
JP2004525962A (ja) 2004-08-26
CN1529603A (zh) 2004-09-15
CZ309042B6 (cs) 2021-12-22
EP1379254B1 (en) 2007-06-20
PL211438B1 (pl) 2012-05-31
ES2289137T3 (es) 2008-02-01
NO333910B1 (no) 2013-10-14
KR20030092063A (ko) 2003-12-03

Similar Documents

Publication Publication Date Title
BR0208924A (pt) Uso de conjugados de ácido graxo de sal biliar ou de ácido biliar
BR9909908A (pt) Derivados de ácidos graxos de ácidos biliares e derivados de ácidos biliares
BR0112104A (pt) Processos para tratamento de doenças reumáticas usando uma molécula de ctla4 solúvel
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
BR0109983A (pt) Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes
BR0308784A (pt) Miméticos de glucocorticóides, métodos para fabricar os mesmos, composições farmacêuticas e usos dos mesmos
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR9809342A (pt) Composto, composição farmacêutica, e, uso do composto
BR0113590A (pt) 7-oxo-piridopirimidinas
JP2004525962A5 (pt)
BR0309421A (pt) Composições de proteìna associada com corpo oleoso e métodos de uso destas para reduzir o risco de doença cardiovascular
BR9914929A (pt) Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
KR960030947A (ko) src SH2 특이성 화합물의 골흡수 질환 치료 용도
KR940021064A (ko) 프레그네인 유도체의 사용 방법
BRPI0413481A (pt) cascas de lêvedos para o tratamento ou a prevenção da hiperglicemia ou para a estabilização da glicemia
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
TR200100897T2 (tr) Lipid metabolizma bozukluklarının tedavisinde safra asitleriyle bağlı propanolamin türevleri.
BR0306778A (pt) Derivados de carboxamidina e seu uso no tratamento de doenças vasculares
BR0008479A (pt) Agonistas de 5-ht 1f

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA.INT.CI.A61K 31/575, A61K 47/48, A61P 3/06

Ipc: A61K 31/575 (2011.01), A61K 47/48 (2011.01), A61P

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B15K Others concerning applications: alteration of classification

Ipc: C07J 9/00 (2006.01), A61K 31/575 (2006.01), A61K 4